{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 2:', 'Schedule of Activities: Extension Period', 'Clinical', 'Period', 'Open-Label Extension', 'Deterioration\u00b9', 'Study Visit', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', 'D925/', 'ET\u00b3/', 'Study Days\u00b2', 'D183', 'D197', 'D211', 'D253', 'D267', 'D309', 'D365', 'D421', 'D477', 'D533', 'D589', 'D645', 'D701', 'D757', 'D813', 'D869', 'EOS', 'W', 'Weeks', 'W26', 'W28', 'W30', 'W36', 'W38', 'W44', 'W52', 'W60', 'W68', 'W76', 'W84', 'W92', 'W100', 'W108', 'W116', 'W124', '132', 'Window (day)', '3', '7', '+ 7', '7', '7', \"+' 7\", '7', '7', '7', \"' 7\", '7', '7', '7', '+ 7', '7', '7', 'Weight', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital Signs &', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pulse Oximetry4', 'Physical', 'X', 'Examination', 'Abbreviated', 'Physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Examination5', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Medication', 'Non-Drug', 'X', 'X', 'X', 'X', 'Therapy', 'MG Therapy', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Status', 'Hospitalization', 'X', 'X', 'X', 'Status', 'Adverse Events', 'X', 'X', 'X', 'MG-ADL6,1', 'X', 'X', 'QMG6, 8', 'X', 'X', 'X', 'X', 'X', 'MG-QOL15r', 'X', 'Neuro-QOL', 'X', 'Fatigue', 'EQ-5D-5L', 'X', 'MGC6,', 'X', 'X', 'X', 'X', 'MGFA-PIS6', 'C-SSRS Since', 'Last Visit', 'X', 'X', 'X', 'X', 'Version', 'ECG', 'AChR Ab', 'X', 'X', 'X', 'Clinical Lab', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Tests9', 'Page 23 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 2:', 'Schedule of Activities: Extension Period (Continued)', 'Clinical', 'Period', 'Open-Label Extension', 'Deterioration\u00b9', 'Study Visit', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', 'D925/', 'ET\u00b3/', 'Study Days\u00b2', 'D183', 'D197', 'D211', 'D253', 'D267', 'D309', 'D365', 'D421', 'D477', 'D533', 'D589', 'D645', 'D701', 'D757', 'D813', 'D869', 'EOS', 'W', 'Weeks', 'W26', 'W28', 'W30', 'W36', 'W38', 'W44', 'W52', 'W60', 'W68', 'W76', 'W84', 'W92', 'W100', 'W108', 'W116', 'W124', '132', 'Window (day)', '3', '7', '+ 7', '7', '7', '7', '+ 7', '+ 7', '7', '+7', '7', '7', '7', '+ 7', '7', '7', 'Pregnancy', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Test10', 'PK, Free C511', 'P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T', 'X', 'ADA11', 'X', 'X', 'X', 'Patient Safety', 'Information', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Card12', 'Ravulizumab', '13', 'X', 'X', 'X', 'Infusion\u00b9', '1 Evaluation of Clinical Deterioration must be performed as soon as possible, within 48 hours of notification to the Investigator of symptom onset.', 'If', 'Clinical', 'Deterioration occurs between scheduled visits, only the assessments for the Clinical Deterioration visit are needed. If Clinical Deterioration occurs on a', 'scheduled visit, all scheduled assessments should be performed for that visit as well as for the evaluation of Clinical Deterioration. Additional', 'evaluation', 'visits', 'can be scheduled at the discretion of the Investigator.', '2', 'Extension Period begins at the start of Day 183 (Week 26) dosing.', '3 If a patient withdraws early from the study during the Extension Period an Early Termination Visit will be performed.', '4 Vital signs and pulse oximetry will include systolic and diastolic blood pressure (millimeters of mercury [mmHg]), pulse oximetry (oxygen saturation [SO2]),', 'heart rate (beats/minute), and temperature (degrees Celsius [\u00b0C] or degrees Fahrenheit [\u00b0F]). On dosing days, vital signs will be taken before study drug', 'administration and after the patient has been resting for at least 5 minutes.', \"5 To be performed, if necessary, on the basis of the patient's health status and the clinical judgment of the Investigator.\", '6', 'Refer to Section 4.2.4.', '7 The MG-ADL is required to be performed first, followed by the QMG. The MG-ADL should be performed by a Properly Trained Clinical Evaluator (as', 'defined in the study protocol), preferably the same evaluator, throughout the study. The recall period for MG-ADL is the preceding 7 days or since the last visit', 'if the visit interval is less than 7 days.', '8', 'The QMG and MGC assessments should be performed by a Properly Trained Clinical Evaluator (as defined in the study protocol), preferably the same', 'evaluator, throughout the study. If a patient is taking a cholinesterase inhibitor, the dose must be withheld for at least 10 hours prior to the assessment.', '9 Clinical laboratory tests will be performed at the central laboratory.', '10', 'Pregnancy tests must be performed on all patients of child-bearing potential at the specified time points. Serum pregnancy tests will be performed at', 'Day 925/ET/EOS; urine pregnancy tests will be performed locally at all other required time points. A negative urine test result performed locally is required', 'prior to administering ravulizumab to patients of childbearing potential at the indicated visits. Additional pregnancy tests (urine or serum) may also be', \"performed at any visit at the Investigator's discretion.\", 'Page 24 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}